Pfizer’s Covid vaccination data for children under 5 may come in late October, says the CEO
Albert Bourla, CEO of Pfizer, addresses a press conference after a visit to monitor the production of the Pfizer-BioNtech COVID-19 vaccine at the factory of the American pharmaceutical company Pfizer in Puurs, Belgium, on December 23. April 2021.
John Thys | Swimming pool | Reuters
Pfizer plans to release clinical trial data on how well its Covid-19 vaccine works in children 6 months to 5 years old, by the end of October, CEO Albert Bourla said Tuesday.
Covid vaccination data for children between the ages of 5 and 11 will come much sooner, he said, potentially ready to be submitted to the Food and Drug Administration by the end of this month.
“Next, it’s up to the FDA to take its time, and then make a decision,” Bourla said during an interview with Research! The 2021 National Health Research Forum of America.
The CEO’s comments come when several parents say they are anxious to vaccinate their children, especially when schools reopen and the highly contagious delta variant continues to spread. The strain has led to an increase in hospitalizations in the United States, even among children who are currently ineligible to receive the blows.
To date, the Pfizer-BioNTech coronavirus vaccine has been released by the FDA for people 12 years of age, while the Modern and Johnson & Johnson vaccines have been approved for adults.
On Friday, FDA officials said they were “working 24 hours a day” to support the approval of Covid vaccines for children under 12 years of age.
Dr Peter Marks, the agency’s first vaccine regulator, said last month the agency would move as “soon” as possible by approving the vaccine for children under 12 once companies present data.
“Currently, there are still ongoing processes and so the agency has to wait for the company to submit the data for these processes,” he said on August 23rd.
Source link
